Flora Peyvandi / X
Jun 26, 2025, 12:53
Flora Peyvandi: Chinese Researchers Smoothly Enter the Gene‑Therapy Arena as the Fight for Hemophilia B Heats Up
Flora Peyvandi, Professor of Internal Medicine at the University of Milan and former President of ISTH, posted on X:
”First Chinese HB gene therapy: ISTH2025”
They say it’s better to prevent than treat—so naturally, ISTH 2025 turned into a gene‑therapy playground for Hemophilia B.
The clinical gene sessions are serving up some seriously insightful management intel!
Stay updated on the latest breakthroughs in Hematology: Hemostasis Today.
-
Apr 10, 2026, 01:19Heghine Khachatryan: When Vascular Fragility Defines Risk – Rethinking Hemostasis in LDS
-
Apr 9, 2026, 21:39Mechanisms of Immune Dysregulation in Immune Thrombocytopenia – JTH
-
Apr 9, 2026, 21:37Arun V J: The Nation Inside the Human Body and Blood Function
-
Apr 9, 2026, 21:36José Antonio García Erce: Fall of While Blood Donation And Apheresis Growth in Spain
-
Apr 9, 2026, 21:34Chokri Ben Lamine: High-Yield Clinical Insights on Carfilzomib-Induced aHUS
-
Apr 9, 2026, 21:29Satyam Arora: Improving Thalassaemia Care in India Through Ground-Level Data
-
Apr 9, 2026, 20:33Pat Garcia-Gonzalez: On World Health Day, I’m thinking about what ‘health’ really means
-
Apr 9, 2026, 19:13Jan Sloves: Patterns and Pitfalls Influencing Treatment of Small Saphenous Vein Reflux
-
Apr 9, 2026, 18:38Jecko Thachil: Why D-dimers are Useful Tests for the Exclusion of Thromboembolism and the Diagnosis of DIC